Gemphire Therapeutics Inc. was a big mover last session, as its shares rose over 12% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up over 20% in the past one-month time frame.

The company has seen one negative estimate revision in the past 30 days, while its Zacks Consensus Estimate moved higher over the same time frame, suggesting more solid trading ahead. So make sure to keep an eye on this stock going forward to see if yesterday’s jump can turn into more strength down the road.

Gemphire Therapeutics currently carries a Zacks Rank #3 (Hold).

Gemphire Therapeutics Inc. Price

 

Gemphire Therapeutics Inc. Price | Gemphire Therapeutics Inc. Quote

A better-ranked stock in the Medical - Biomedical and Genetics space is Heska Corporation , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
    
More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple sold a mere
1 billion iPhones in 10 years but a new breakthrough is expected to generate more
than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging
phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may
kick yourself in 2020. Click here for the 6 trades >>